Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
Patients with atrial fibrillation
Edoxaban (once-daily regimens)
Warfarin
Stroke or systemic embolismcomposite
Once-daily edoxaban is noninferior to warfarin for stroke prevention in atrial fibrillation and reduces the risk of bleeding and cardiovascular death.
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Robert P. Giugliano
Christian T. Ruff
Eugene Braunwald
New England Journal of Medicine
Harvard University
Brigham and Women's Hospital
McMaster University
Building similarity graph...
Analyzing shared references across papers
Loading...
Giugliano et al. (Tue,) reported a other. Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
www.synapsesocial.com/papers/69813150ce4d1f8e18d4e85d — DOI: https://doi.org/10.1056/nejmoa1310907